Immunocore Expands IO Pact With Genentech To Target MAGE-A Antigens
Executive Summary
Genentech and Immunocore will now co-develop the biotech's therapeutic candidate IMC-C103C, an ImmTAC molecule targeting tumors that express melanoma-associated antigen A4.
You may also be interested in...
Jallal To Lead Immunocore, Building On Partnership She Forged At MedImmune
A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Gates Foundation’s $40m Incentivizes Cancer Specialist Immunocore To Develop TB, HIV Drugs
Oxford, UK-based Immunocore, which is developing immunotherapies against cancer, has secured $40m in funding from the Bill & Melinda Gates Foundation to boost its research activities in infectious diseases. The company hopes to develop novel therapeutics to reduce treatment timelines and improve outcomes for patients with HIV and TB.